アルファ-シヌクレイン遺伝子プロモーターの変動性とパーキンソン病の共同分析
Demetrius M Maraganore1, Mariza de Andrade, Alexis Elbaz
1Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. dmaraganore@mayo.edu
JAMA
|August 10, 2006
まとめ
パーキンソン病のリスクは,SNCA遺伝子の変異と関連しています.
科学分野:
- 遺伝学 遺伝学とは
- 神経科学は神経科学である.
- エピデミオロジー エピデミオロジー
背景:
- 以前のパーキンソン病 (PD) 遺伝学的研究は,小さなサンプルサイズと潜在的なバイアスによって制限されていました.
- アルファ-シヌクレイン (SNCA) 遺伝子は主要な疑わしいものですが,大規模な検証は行われませんでした.
研究 の 目的:
- SNCA遺伝子プロモーターREP1アレル長の変化性とパーキンソン病の感受性との関連を調べる.
- SNCAプロモーターハプロタイプがパーキンソン病のリスクに影響するかどうかを調べる.
- REP1の変動がパーキンソン病の発症年齢に影響するかどうかを判断する.
主な方法:
- 11のグローバルサイトからの個々の患者データの共同分析.
- パーキンソン病の2692例と2652例の対照群におけるSNCA REP1と側面マーカーのゲノタイプ化.
- 統計分析には,ハーディ・ワインバーグの均衡,異質性テスト,関連研究,生存分析が含まれていた.
主要な成果:
- パーキンソン病症例と対照群 (P<.001) の間で,SNCA REP1アレル頻度の有意な違いが観察されました.
- SNCA REP1の263塩基対アレルは,パーキンソン病のリスクの増加と関連していました (OR,1.43;P<.001).
- REP1を含むマルチロカスハプロタイプはパーキンソン病と関連していたが,RP1の変動性は発症時の年齢に影響しなかった (P = .55).
結論:
- この大規模な研究は,SNCA REP1アレル長さの変動がパーキンソン病のリスク増加と関連していることを確認しています.
- この発見は,パーキンソン病の病原性におけるSNCA REP1の重要性を強調しています.
さらに関連する動画
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
11.9K
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
10.2K
関連する概念動画
Pleiotropy
31.2K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.2K
Incomplete Dominance
19.0K
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
19.0K
Comparing Copy Number Variations and SNPs
11.6K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
11.6K
Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
